MSB

2.51%

97.0¢ mesoblast limited

Could you repeat that please?

First 10486 Last

Share
Profile

Follow
whytee

16,756 Posts.

2392

04/08/24

16:19

Post #: 75063579
Share

Originally posted by irenekwshiu ↑

Hi @otherperspective, I just had another read and found your comment worth repeating:

“In my opinion , Mesoblast shares in the next 12 months are about to go on a run of epic proportions, provided we are granted approval for the Ryoncil BLA resubmission. The latter is being used as a “bellwether “ indication for a whole host of inflammatory orphan designation diseases as well as some “blockbuster “ indications. The catalyst , for a big chunk of this rerating apart from establishing much needed credibility and validation…is that reality has set in at the FDA. Peter Marks should be given credit for reappraising the Accelerated Pathway so that it stimulates investment into unmet needs. This will allow early commercialisation of perfectly safe regenerative medicines who are falling slightly short of clinical trial requirements which are more appropriate for small molecules therapies which are generally immunosuppressive rather than immunomodulators. Regenerative medicine , has had the added burden of needing potency assays to ensure consistency of product so that every patient receives a uniform product regardless of individual donor profile . IMO, if Mesoblast has finally cracked the potency assay issues it will become one of the most sought after stocks in healthcare portfolios. Within five years , it would not surprise me if the market capitalisation was closer to US$100bn. I know the latter comment will leave me open to ridicule but just remember the market for chronic lower back pain alone is at least US$ 3bn based on a lowball $15k wholesale price per outpatient procedure . If the FDA is serious about accelerated approval then they must surely apply that process to the best potential therapy for solving the opioid crises in the USA ! Go figure ! OP

Please do not rely on the facts or opinions expressed in the above post when making an investment decision. I am not medically qualified.”

Expand

Could you repeat that please?

MSB Price at posting: 97.0¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GRX

GreenX picks up prospective copper project in Germany

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

There are more pages in this discussion • 4 more messages in this thread...

First 10486 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 97.0¢		Change -0.025(2.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
97.0¢	$1.01	96.5¢	$7.757M	7.884M

Buyers (Bids)

No.	Vol.	Price($)
10	274918	97.0¢

Sellers (Offers)

Price($)	Vol.	No.
97.5¢	974	1

View Market Depth

No.	Vol.	Price($)
6	103162	0.970
5	34741	0.965
11	125566	0.960
1	500	0.955
22	165429	0.950

Price($)	Vol.	No.
0.975	974	1
0.990	10204	1
1.000	14000	1
1.010	2877	1
1.015	60000	1

Last trade - 16.10pm 02/08/2024 (20 minute delay)

MSB (ASX) Chart

Could you repeat that please?

Venture to sniff out high-grade REE targets at Jupiter project, WA

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Could you repeat that please?

Top Stories

Venture to sniff out high-grade REE targets at Jupiter project, WA

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Is oil undervalued?

Cost blow-out for Rook I uranium project sees share plummet for NexGen

GreenX picks up prospective copper project in Germany

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News